U
Ulrich Abel
Researcher at German Cancer Research Center
Publications - 81
Citations - 4640
Ulrich Abel is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Population & Prostate cancer. The author has an hindex of 33, co-authored 79 publications receiving 4399 citations. Previous affiliations of Ulrich Abel include University Hospital Heidelberg & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Nathalie Cartier,Salima Hacein-Bey-Abina,Cynthia C. Bartholomae,Gabor Istvan Veres,Manfred Schmidt,Ina Kutschera,Michel Vidaud,Ulrich Abel,Liliane Dal-Cortivo,Laure Caccavelli,Nizar Mahlaoui,Veronique Kiermer,Denice Mittelstaedt,Céline Bellesme,Najiba Lahlou,François Lefrère,Stéphane Blanche,Muriel Audit,Emmanuel Payen,Philippe Leboulch,Philippe Leboulch,Bruno l’Homme,Pierre Bougnères,Christof von Kalle,Alain Fischer,Marina Cavazzana-Calvo,Patrick Aubourg +26 more
TL;DR: Lentiviral-mediated gene therapy of hematopoietic stem cells can provide clinical benefits in ALD, and progressive cerebral demyelination in the two patients stopped, a clinical outcome comparable to that achieved by allogeneic HCT.
Journal ArticleDOI
Distinct types of tumor-initiating cells form human colon cancer tumors and metastases
Sebastian M. Dieter,Claudia R. Ball,Christopher M. Hoffmann,Ali Nowrouzi,Friederike Herbst,Oksana Zavidij,Ulrich Abel,Ulrich Abel,Anne Arens,Wilko Weichert,Karsten Brand,Moritz Koch,Jürgen Weitz,Manfred Schmidt,Christof von Kalle,Hanno Glimm +15 more
TL;DR: It is demonstrated that tumor initiation, self-renewal, and metastasis formation are limited to particular subpopulations of TICs in primary human colon cancer.
Journal ArticleDOI
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy
Annette Deichmann,Salima Hacein-Bey-Abina,Manfred Schmidt,Manfred Schmidt,Alexandrine Garrigue,Martijn H. Brugman,Jingqiong Hu,Hanno Glimm,Gabor Gyapay,Bernard Prum,Christopher Fraser,Nicolas Fischer,Kerstin Schwarzwaelder,Kerstin Schwarzwaelder,Maria Luise Siegler,Dick de Ridder,Dick de Ridder,Karin Pike-Overzet,Steven J. Howe,Adrian J. Thrasher,Gerard Wagemaker,Ulrich Abel,Frank J. T. Staal,Eric Delabesse,Jean-Luc Villeval,Bruce J. Aronow,Christophe Hue,Claudia Prinz,Manuela Wissler,Chuck Klanke,Jean Weissenbach,Ian E. Alexander,Alain Fischer,Christof von Kalle,Marina Cavazzana-Calvo +34 more
TL;DR: The results obtained from a large-scale mapping of retroviral integration sites isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID- X1.
Journal ArticleDOI
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo
Kerstin Schwarzwaelder,Steven J. Howe,Manfred Schmidt,Manfred Schmidt,Martijn H. Brugman,Annette Deichmann,Annette Deichmann,Hanno Glimm,Hanno Glimm,Sonja Schmidt,Claudia Prinz,Manuela Wissler,Douglas King,Fang Zhang,Kathryn L. Parsley,Kimberly Gilmour,Joanna Sinclair,Jinhua Bayford,Rachel Peraj,Karin Pike-Overzet,Frank J. T. Staal,Dick de Ridder,Dick de Ridder,Christine Kinnon,Ulrich Abel,Gerard Wagemaker,H. Bobby Gaspar,Adrian J. Thrasher,Christof von Kalle +28 more
TL;DR: The divergence of RIS target frequency between transduced progenitor cells and post-thymic T lymphocytes indicates that vector integration influences cell survival, engraftment, or proliferation.
Journal ArticleDOI
Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH
A. Weirich,Ivo Leuschner,Dieter Harms,Gordan M. Vujanic,Jochen Tröger,Ulrich Abel,Norbert Graf,D. Schmidt,R. Ludwig,P. A. Voute +9 more
TL;DR: Subtyping according modified Beckwith & Palmer can be used in Wilms' tumor after preoperative therapy to stratify postoperative therapy in future.